


DIGNITANA

Clinically superior scalp cooling

AUGUST 17 • 2023



**15 percent revenue growth
driven by improved utilization**

Q2 23

QUARTERLY REPORT

15 percent revenue growth driven by improved utilization

Financial highlights Q2 2023

- Net sales amounted to 21.1 MSEK (18.3), an increase of 15 percent over the same period in 2022
- Operating result amounted to -4.7 MSEK (+0.1).
- Net result after financial items amounted to -4.7 MSEK (-0.2).
- Earnings per share were -0.07 SEK (0.00).
- Cash Balance amounted to 5.4 MSEK (7.3).
- Average Daily Treatment Revenue (ADTR)* was 241 TSEK (201), an increase of 20 percent over the same period in 2022.

Business highlights during the period

- Dignitana announced a proposal for Local Coverage Determination of scalp cooling therapy for seven states in the Southeastern United States.
- Dignitana exhibited at the Oncology Nursing Congress in San Antonio, Texas.
- Dignitana co-sponsored a scalp cooling session at the Multinational Association of Supportive Care in Cancer conference in Japan along with exhibiting at the conference.
- In May Dignitana published the Annual Report for 2022.
- Dignitana's Annual General Meeting was held on 25 May 2023.

”

With a focus on device utilization, our circular business model creates, captures and delivers value by redeploying underutilized devices and thus maximizing revenue potential and fostering sustainable use of assets.

– Catarina Löwenadler, CEO

Business highlights after the period

- Five year follow up results from the DigniCap pivotal trial were published in the Journal of Supportive Care in cancer demonstrating both safety and efficacy in the first long term study of scalp cooling.
- Dignitana announced that the partnership with oneservice has expanded to now provide service in the field to DigniCap customers in Europe.
- DigniCap Delta was introduced to customers in Mexico by Celeritas, DigniCap's longtime partner there.

Key Figures

DIGNITANA GROUP	Q2 2023	Q2 2022	Q1-Q2 2023	Q1-Q2 2022	FY 2022
Net sales, TSEK	21,089	18,284	42,578	34,148	72,995
Total revenues, TSEK	23,159	24,067	44,764	40,777	83,849
Net profit after financial items, TSEK	-4,662	-232	-8,600	-6,740	-22,396
Cash and bank balances, TSEK	5,423	7,312	5,423	7,312	8,869
Earnings per share before and after dilution, SEK	-0.07	0.00	-0.12	-0.10	-0.34
Average Daily Treatment Revenue, TSEK	241	201	242	190	203

* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

DIGNITANA'S VISION IS TO ENSURE THAT CANCER PATIENTS CAN MAINTAIN DIGNITY AND QUALITY OF LIFE DURING AND AFTER CANCER TREATMENT.

15 percent revenue growth driven by improved utilization

Happy patients are at the center of all that we do, but even deeper than happiness is the concept of dignity, and at its core Dignitana represents dignity. It is a quality that is identified with characteristics like confidence, self-respect and demeanor – and multiple studies have shown that a patient who has dignity during cancer treatment has enhanced quality of life and improvements in overall wellness. Thus, I am happy to report that we have seen impressive results from our ongoing patient satisfaction surveys - 94 percent of DigniCap patients would recommend DigniCap to others and 75 percent of DigniCap patients report a high degree of satisfaction with their DigniCap experience. These extraordinary numbers are driven by our commitment to customer service, proven efficacy, and ease of use, and we will continue to do all we can to support the patient journey with dignity and respect.

Dignitana's growth is progressing at a steady pace as we continue to follow our growth strategy and deliver according to plan. In the second quarter, Net Sales posted a 15 percent increase over same period 2022, and our primary utilization metric, Average Daily Treatment Revenue, increased 20 percent over Q2 2022. Our monthly KPIs show continued growth with high margin, and we have confidence that this is the progress needed to support advancement toward our broader financial objectives.

Last year we launched a scale-up strategy focusing on strategic initiatives to support the company's financial objectives. Although this strategy is taking a little more time than anticipated to fully implement, as we reinvest to continue the scale up strategy, we are seeing consistent growth each period, and we are confident this will pay off to a greater degree going forward.

With a focus on device utilization, our circular business model creates, captures and delivers value by redeploying underutilized devices and thus maximizing revenue potential and fostering sustainable use of capital.

To further support our verified strategy, we have taken this quarter to make several necessary investments in the areas of marketing, reimbursement, and operations, as detailed here. We were happy to establish a strong presence at the Multinational Association of Supportive Care in Cancer Conference in Japan in June. This single event provided us with the opportunity to co-sponsor a scalp cooling session that was filled to capacity, in addition to the presentation and publication of data from the five-year follow up of the Dignitana clinical trial – significant as it is the first long term study of scalp cooling.

Reimbursement and market access remain a primary initiative central to the company's growth, requiring ongoing investment and expertise. In the second quarter we supported a Local Coverage Determination for Scalp Cooling proposed for Medicare patients in the southeastern United States and hope to hear a decision on that initiative soon. As we push to establish scalp cooling as standard of care, more payers are now reimbursing for scalp cooling. We are working to capitalize on this trend by expanding our Buy and Bill model. This means customers need to transition from our easy and no-risk direct pay model, to a traditional buy and bill model that has a tremendous financial upside but does incur some financial risk for the provider. Introducing this transition requires time and resources, but we are seeing progress on this front.

In Operations, we have made two important advancements related to service in the second quarter. The first is the ability to offer service in the field. Over the past several months we have trained service technicians, and now can offer customers in Europe and Rest of World a three-fold benefit of convenience, reduced time and cost savings by completing service in the field rather than shipping devices back and forth. Related to this ability, we have expanded our partnership with oneservice, and they will now handle service and maintenance for DigniCap Delta customers in Europe. We are excited about this development and welcome the opportunity to broaden the scope of work with an existing partner so that we can continue to operate efficiently and reach even more patients. Globally, we are starting to see the effect of the investment in good technical support through strong relationships with the right partners. This has led to orders for additional devices in Hong Kong and Uruguay in the second quarter as well as the introduction of DigniCap Delta in Mexico.

As a company we find our purpose in dignity. I am proud of the hard work that our team is doing each and every day. With the continued support of our shareholders, we are making progress toward our business objectives, we are improving the quality of life for patients, and we are providing dignity to those who need it most.



Catarina Löwenadler, CEO
Dignitana AB

The Company

Dignitana AB is a medical technology company based in Lund, Sweden and publicly traded on Nasdaq First North Growth Market in Sweden. Company headquarters are in Lund, Sweden and U.S. operations are based in Dallas, Texas. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Redeye AB is Certified Adviser.

The Company produces The DigniCap Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. The DigniCap Scalp Cooling System was invented in 1999 by a Swedish oncology nurse. DigniCap has been on the market in Europe since 2001 and has had FDA clearance since 2015 to provide continuous scalp cooling with high efficacy, safety, and acceptable patient comfort. In 2017 Dignitana received expanded clearance from the FDA allowing DigniCap to be used by patients receiving chemotherapy to treat other solid tumors in addition to

the original indication for use by patients with breast cancer. In 2019 Dignitana introduced the next generation DigniCap Delta. The technologically advanced DigniCap Delta model received CE Marking and FDA clearance that year, as well as regulatory approvals in Australia and Israel.


Scalp cooling is recognized as standard of care by numerous organizations around the world. European Society for Medical Oncology (ESMO) added scalp cooling as a Category IIB treatment recommendation in 2020 and Cancer Australia added scalp cooling to its Fall 2020 update providing guidance for the management of early breast cancer patients. In the United States clinical recommendations introduced in 2019 and 2020 by the National Comprehensive Cancer Network® and a policy reaffirmation by the American Medical Association in 2022 all contribute to a solid foundation for scalp cooling to become standard of care in the United States.

Business model

Dignitana has two business models that each include an ongoing revenue stream from the sale of consumables. In the United States devices are leased to providers and the Company utilizes a pay-per-treatment model. The availability of scalp cooling continues to expand as we work toward scalp cooling becoming standard of care providing access to more patients. Dignitana offers a buy and bill model that supports reimbursement initiatives. As reimbursement and coverage become more predictable, we

will transition providers to this model that is widely used in healthcare.

Outside the U.S. devices are sold to medical facilities and the company also receives revenue from service and maintenance agreements. For global markets that do not have a pay-per-treatment model, the focus is on creating a more sustainable recurring revenue stream from unit sales, lease agreements, service and maintenance fees, and sales of product disposables and supplies.



Reimbursement

Dignitana is committed to ensuring scalp cooling is available to every cancer patient and reimbursement is a critical factor in patient access and affordability. Health care providers are key partners in our efforts to increase accessibility to improve quality of life for as many cancer patients as possible. Dignitana recognizes that providers allocate a range of resources to scalp cooling therapy and their clinical expertise, direct patient care, and skilled operation of the DigniCap device by trained personnel ensure that DigniCap patients have the most successful clinical outcomes possible. The buy and bill model Dignitana offers facilitates a pathway for providers to be reimbursed for the specialized service they are providing to patients.

Since 2021 Dignitana has led the way in reimbursement efforts for scalp cooling in the U.S., including work supporting the introduction of CPT® codes for scalp cooling and a rate assignment from the Centers for Medicare & Medicaid Services (CMS) that was introduced in 2022. Dignitana continues to work with healthcare providers and payers to advance reimbursement of scalp cooling.

The latest reimbursement progress occurred In June 2023 when the Palmetto Medicare Administrative Contractor (MAC), which administers Medicare benefits in seven states in the southeastern United States, issued a Proposed Local Coverage Determination (LCD) for scalp cooling. If approved this would provide a pathway for successful reimbursement of Medicare claims for patients in the seven-state service area as soon as 2024. This is the first such LCD and further advances support for health care providers to receive reimbursement from Medicare to administer FDA-cleared scalp cooling therapy.



The market

The market

DigniCap minimizes chemotherapy-induced hair loss for cancer patients with solid tumors. Globally there are over 17 million incidences of cancer diagnosed annually, with 1.9 million diagnoses occurring in the U.S. each year, and by 2040 the global cancer burden is projected to reach 28 million new incidences solely due to growth and aging of the population. In the U.S. it is estimated that 39 out of 100 women and 40 out of 100 men will develop cancer during their lifetime.

Scalp cooling is primarily used today during the treatment of breast cancer, the most common type of cancer in the world. Globally 2.3 million cases of breast cancer are diagnosed annually, with 291,000 of those in the United States. Scalp cooling is also used by patients with other solid tumors such as ovarian, uterine, endometrial, cervical, and prostate cancers. Non-breast solid tumors represent nearly one million patients in the U.S annually.

Dignitana estimates that up to 60 percent of all cancer patients are on regimens that are compatible with DigniCap. Additionally published studies have found that 8-10 percent of female patients refuse chemotherapy due to concern over hair loss, and 96 percent of potential patients surveyed were interested in scalp cooling

Market development

The DigniCap Scalp Cooling System is clinically proven to reduce hair loss in cancer patients undergoing chemotherapy for solid tumors. The DigniCap Scalp Cooling System has been marketed worldwide since 2009 and received FDA clearance for the US market in 2015. DigniCap was the first scalp cooling system to receive FDA clearance, with only two other systems now on the market that received clearance more recently.

The DigniCap Delta model was introduced in 2019 and is a smaller, single-patient device providing optimal outcomes and improved ease of use for clinicians and patients. In 2019 DigniCap Delta received CE Marking for Europe and FDA clearance for the U.S., followed by TGA clearance for Australia.

To increase awareness and utilization of scalp cooling Dignitana works with patient advocacy organizations and interest groups in the cancer care community. Dignitana's ongoing sponsorship of Susan G. Komen, the largest breast cancer advocacy group in the world, is an example of this, in addition to numerous partnerships with foundations across the United States.

In most of the world scalp cooling is not a standard option for cancer care. The acceptance, market penetration and utilization of this treatment vary widely, providing significant opportunities for Dignitana all over the world.

Dignitana is committed to advancing the science of scalp cooling by supporting clinical trials and research initiatives among DigniCap users. The Company has initiated several studies that could expand usage to new user groups and show improvements with existing regimens that have exhibited inferior results with scalp cooling previously.



”

My cancer was very aggressive. The one thing that I could hold on to was my identity. It was really important for me to keep my hair so I could see myself in the mirror and not the cancer.

Nelly

Financial information and comments

DIGNITANA GROUP

Revenues

Group revenues are generated by direct sales of systems, leasing of systems to health care providers, pay-per treatment fees, service and maintenance agreements, sales of individual caps and kit accessories. For the second quarter 2023 net sales amounted to 21,089 TSEK (18,284), an increase over the same period 2022 by 2,805 TSEK representing 15 percent growth.

Dignitana operates by two business models: in the U.S. market DigniCap Delta systems are leased to health care providers and the Company generates revenues from the leasing contracts through monthly leasing fees as well as payment for treatments and sales of products related to patient treatments. Outside the U.S, revenues are generated by sales of DigniCap Delta systems, frequently combined with service and maintenance agreements, as well as the sale of patient-related products and consumables.

The U.S. market is still the driver in placing DigniCap Delta on the market using the leasing business model. In the first half of 2023 Company has continuously focused on reallocating weak utilized machines in some facilities to higher usage facilities with increasing demand. This enables the Company to reach more patients and improve patient outcomes and thereby achieve higher growth. Reallocation of devices to optimize utilization will continue as part of normal business operations as the market develops.

Dignitana's revenue and costs comprise of different currencies such as USD, EUR, and SEK. Operational exchange rate balance effects are recognized in the income statement under other operating income and in other operating expenses. In Q2 2023 net exchange rate effects amounted to 97 TSEK (5,708). In 2022 internal loans were redirected from USD to SEK and this will reduce the revaluation effect related to exchange fluctuations in 2023.

In Q2 2023 reserves for items in working capital were adjusted affecting other operating income by positive 1,904 TSEK.

Operating Expenses and Operating Result

Operating expenses including Personnel expenses increased during the quarter compared to the same period last year by 2,000 TSEK and amounted to -16,948 TSEK (-14,948). We are increasing activities supporting sales growth and consequently travel and marketing costs increase.

As investments for scale up continue, there are some overlapping costs while shifting from external consultants to employees, but we do not expect operating expenses to grow in the coming quarters.

Depreciation and amortization in the Group amounted to -3,747 TSEK (-3 333).

The operating result after depreciation for the Group for the second quarter was -4,657 TSEK (77). The main differences are related to exchange rate effects and increased marketing activities. Due to the expansion of the expanded partnership with oneservice for maintenance, service and support of DigniCap Delta devices in Europe, we decided to take an additional inventory write-down of -1.0 MSEK related to spare parts for old equipment in Q2.

Financial net

The financial net was -5 TSEK (-309), mainly affected by debt-related interest and a positive net on exchange effects on balance items.

Employees

At the close of the period the Company had 27 (24) employees.

Cash Flow and Financial Position

Consolidated cash flow from operating activities during the quarter was -3,099 TSEK (-7,244). Total cash flow for the period was -6,453 TSEK (-4,448). Cash and cash equivalents at the end of the quarter amounted to 5,423 TSEK (7,312).

Board and Management are continuously monitoring the financial position of the Company and are of the opinion that current business plans, in conjunction with various available options for credit facilities, are sufficient financial resources to cover working capital needs for the coming 12-month period.

CAPEX

Capex amounted to 2,312 TSEK (255) in the quarter in tangible assets.

The share

Dignitana has been listed on First North Growth Market since November 2011 after having been listed on Spotlight Market in Stockholm since June 2009.

Dignitana AB

TICKER	DIGN
Market Cap June 30	280 MSEK
Number of shareholders, approximately	2,328
Share price June 30	3.98 SEK
Number of shares traded during the quarter	463,759
Number of shares outstanding June 30	70,474,155
Registered share capital	7,047,416 SEK
Par value	0.1 SEK
Certified Adviser	Redeye

Dignitana has only one category of shares, where each share carries one vote and equal rights to the Company's assets and profits. The Company has over time issued new shares and stock option programs and at the general meeting in May 2023 a decision was taken to issue a maximum of 1,800,000 employee warrants to key employees of the Company resulting in capital of 680KSEK in Q2 2023. The period for the employee stock warrants runs from June 2023 to June 2026.

Largest Shareholders

30 JUNE 2023	HOLDINGS	PERCENT
AGARTHA AB	20,500,000	29.09%
SWEDBANK ROBUR MICROCAP	5,415,000	7.68%
HANDELSBANKEN MICROCAP SVERIGE	5,285,429	7.5%
AVANZA PENSION	4,722,502	6.7%
CBLDN-UBS FINANCIAL SERVICES INC	4,189,739	5.95%
FÖRSÄKRINGSAKTIEBOLAGET SKANDIA (PUB)	2,608,714	3.70%
FE SMÅBOLAG SVERIGE	1,799,900	2.54%
TECHNOVOBIS AB	1,790,593	2.54%
POURSAMAD, AMIR	1,500,929	2.13%
RÜLF, SEMMY	1,015,058	1.44%
TOTAL	48,827,864	69.28%
OTHER SHAREHOLDERS	21,646,291	30.72%
TOTAL	70,474,155	100.00%

Source: Euroclear



”

We were renewing our wedding vows just 9 months after I completed my 20-week chemotherapy regimen, and I was so happy to still have my long hair for the photos.

I am so thankful I was told about DigniCap and that it was an option.



- Melanie

Risk factors

An investment in securities is associated with risk. Dignitana's activities are affected, and may be affected, by several factors which cannot be completely controlled by the Company. There are risks both in terms of circumstances attributable to Dignitana and those which have no specific connection with the Company.

The non-definitive list of the Company's risks pertains, but is not limited, to: patents, key personnel, growth management, management, restructuring, development costs, competitors, dependence on individual customers, customers, authorization and registration, chemotherapy without side effects, alternative cancer treatment

methods, distributors and manufacturers, profitability and future capital requirements, political risk, geopolitical risks, pandemic risks, regulatory or change of laws, disputes and currency risks.

Risks related to COVID-19

The outbreak of COVID-19 in the spring of 2020 affected the Company's opportunities to reach customers and also customers' ability to offer scalp cooling as a form of treatment. The ongoing burden of the pandemic on the healthcare system is still high, with higher staff turnover and scarcity of resources, and thus there is a risk to the implementation of new treatment methods.

Risks related to the Russian invasion of Ukraine

The company's assessment is that the ongoing military conflict in Ukraine should not have any immediate significant effect on the operations. Indirect effects such as increases in energy costs and transportation, increased lead time of components and general cost increases could have some impact on the operations but are deemed as manageable. If the conflict spreads to more territories, this assessment could change. USA is the group's primary market from a sales and supply perspective.

The Board is ultimately responsible for managing and monitoring these risks. Ongoing management is delegated to the CEO, who in turn reports to the Board.

For a detailed explanation of these risk factors view the 2022 Annual Report posted at <https://dignitana.com/investor-relations/financial-reports/>

Other information

Forward-looking statements

This report may contain statements, estimates or projections that constitute "forward-looking statements." Generally, the words "believe", "expect", "intend", "estimate", "anticipate", "project", "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Dignitana historical experience or future projects.

Accounting principles

The consolidated financial statements comprise of Dignitana AB and its subsidiaries Dignitana Inc. and Dignitana S.r.l.

This interim report is prepared in accordance with Swedish GAAP, BFNR 2012:1 (K3). The accounting policies remain unchanged compared with the preceding year and are the same principles that were applied for the Annual Report 2022.

Financial statements are presented in SEK, the functional currency of Dignitana AB. Assets and liabilities are translated and presented at the closing rate and the Income statement is translated and presented at period average exchange rates.

For a detailed explanation of accounting principles view the 2022 Annual Report posted at

<https://dignitana.com/investor-relations/financial-reports/>

This Interim Report has not been reviewed by the Group's Auditors

Board assurance

The Board of Directors and Chief Executive Officer declare that this Interim Report provides a fair view of the Company's operations, financial position and results, and describes material risks and uncertainties facing the Company.

Dignitana AB

Corporate Registration Number: 556730-5346

Lund, 17 august 2023

Dignitana AB (publ) Board of Directors

Klas Arildsson
Chairman of the Board

William Cronin
Deputy Chairman of the Board

Lina Karlsson
Board member

Richard Dilorio
Board member

Christian Lindgren
Board member

Ljubo Mrnjavac
Board member

Income Statement – Dignitana Group, TSEK

DIGNITANA GROUP	Q2 2023	Q2 2022	Q1–Q2 2023	Q1–Q2 2022	Full year 2022
Operating Income					
Net sales	21,089	18,284	42,578	34,148	72,995
Capitalized work for own account	0	0	0	0	431
Other operating income	2,070	5,783	2,186	6,629	10,423
Total Operating Income	23,159	24,067	44,764	40,777	83,849
Operating expense					
Goods for Resale	-7,121	-5,709	-13,921	-11,535	-27,049
Operating expense	-7,010	-7,213	-12,797	-14,147	-28,579
Personnel expense	-9,681	-7,498	-18,454	-14,130	-34,289
Depreciation and amortization of tangible and intangible assets	-3,747	-3,333	-7,429	-6,618	-13,799
Other operating expenses	-257	-237	-318	-411	-747
	-27,816	-23,990	-52,919	-46,841	-104,463
Operating profit (loss)	-4,657	77	-8,155	-6,064	-20,614
Result from financial investments					
Other Interest income and similar items	572	186	583	256	616
Interest expenses and similar items	-577	-495	-1,028	-932	-2,398
	-5	-309	-445	-676	-1,782
Profit after financial items	-4,662	-232	-8,600	-6,740	-22,396
Profit before tax	-4,662	-232	-8,600	-6,740	-22,396
Tax on profit for the period	0	0	0	0	-15
Results for the Period	-4,662	-232	-8,600	-6,740	-22,411
Average number of shares before and after dilution	70,474,155	65,059,155	70,474,155	65,059,155	66,130,254
Earnings per share before and after dilution, SEK	-0.07	0.00	-0.12	-0.10	-0.34

Balance Sheet – Dignitana Group, TSEK

DIGNITANA GROUP	2023-06-30 2023	2022-06-30 2022	2022-12-31 2022
ASSETS			
FIXED ASSETS			
Intangible assets			
Capitalized expenses for development	4,861	8,956	7,139
	4,861	8,956	7,139
Tangible assets			
Equipment, tools and installations	171	219	164
Machinery and other technical facilities	46	63	54
Leasing machines	24,890	28,812	26,952
	25,107	29,094	27,170
Financial assets			
Other long term receivables	292	0	175
	292	0	175
Total Fixed Assets	30,260	38,050	34,484
CURRENT ASSETS			
Inventories and similar			
Finished goods and goods for resale	4,960	6,994	5,053
	4,960	6,994	5,053
Current Receivables			
Accounts Receivable	6,233	8,787	6,505
Current Tax Assets	0	89	0
Other Current Receivables	658	1,045	756
Prepaid expenses and accrued income	3,307	2,460	2,884
	10,198	12,381	10,145
Cash and Bank Balances	5,423	7,312	8,869
Total Current Assets	20,581	26,687	24,067
Total Assets	50,841	64,737	58,551
EQUITY AND LIABILITIES			
Equity			
Share Capital	7,047	6,506	7,047
Other contributed capital	246,550	223,070	245,866
Other equity including profit for the year	-236,881	-210,698	-228,663
Total Equity	16,716	18,878	24,250
Provisions			
Other provisions	292	6	187
	292	6	187
Long Term Liabilities			
Other long term liabilities	5,493	13,248	8,614
Total Long Term Liabilities	5,493	13,248	8,614
Current Liabilities			
Liabilities to credit institutions	11,516	9,105	9,653
Accounts payable	3,895	6,636	5,575
Other current liabilities	6,401	6,481	1,909
Accrued expenses and deferred income	6,528	10,383	8,363
Total current liabilities	28,340	32,605	25,500
Total liabilities	33,833	45,853	34,114
Total Equity and Liabilities	50,841	64,737	58,551

Consolidated Statement of Changes in Equity

– Dignitana Group, TSEK

DIGNITANA GROUP	Share capital	Other contributed capital	Retained earnings, incl. net loss for the year	Total equity
Opening equity on 1/1/2022	6,506	222,692	-198,012	31,186
Net loss for the period			-6,740	-6,740
Share warrants		378		378
Option program 2022			480	480
Change in translation difference relating to subsidiaries			-6,426	-6,426
Closing equity on 6/30/2022	6,506	223,070	-210,698	18,878
Net loss for the period			-15,671	-15,671
Share warrants				0
Option program 2022			480	480
New share issue	541	24,314		24,854
Issue costs		-1,518		-1,518
Change in translation difference relating to subsidiaries				
Closing equity on 12/31/2022	7,047	245,866	-228,663	24,250
Net loss for the period			-8,600	-8,600
Share warrants		684		684
Change in translation difference relating to subsidiaries			382	382
Closing equity on 6/30/2023	7,047	246,550	-236,881	16,716

Statement of Cash Flows – Dignitana Group, TSEK

DIGNITANA GROUP	Q2 2023	Q2 2022	Q1–Q2 2023	Q1–Q2 2022	Full year 2022
Operating activities					
Profit after financial investments	-4,662	-232	-8,600	-6,740	-22,396
Adjustments for items not affecting cash flows, etc	4,544	-2,813	8,319	763	6,178
Tax paid	0	-16	-16	-24	-59
Cash flow from operating activities before changes in working capital	-118	-3,061	-297	-6,001	-16,277
Cash flow from changes in working capital					
Change in inventories	-648	456	-797	346	813
Change in other current receivables	330	-3,489	273	-3,329	-1,684
Change in other current liabilities	-2,663	-1,150	-4,257	397	-1,016
Cash flows from operating activities	-3,099	-7,244	-5,078	-8,587	-18,164
Investing activities					
Investments in intangible assets	0	0	0	0	-431
Investments in tangible assets	-2,312	-255	-3,070	-472	-2,790
Proceeds from sale of tangible assets	948	0	948	0	91
Investments in other financial fixed assets	-59	0	-117	0	0
Cash flows from investing activities	-1,423	-255	-2,239	-472	-3,130
Financing activities					
New share issue	0	0	0	0	24,855
Issue expenses	0	0	0	0	-1,518
Options issued	684	378	684	378	378
New loans	0	5,000	5,000	5,000	10,000
Repaid loans	0	0	0	0	-10,000
Changes in long and short term liabilities to credit institutions	-2,615	-2,327	-1,914	-4,039	-8,685
Cash flow from financial activities	-1,931	3,051	3,770	1,339	15,030
Cash flow for the period	-6,453	-4,448	-3,547	-7,720	-6,264
Cash and cash equivalents at beginning of period					
Cash and cash equivalents at beginning of period	11,726	11,311	8,869	14,501	14,501
Exchange-rate differences in cash and cash equivalents					
Exchange-rate differences in cash and cash equivalents	150	449	101	531	632
Cash and cash equivalents at end of period	5,423	7,312	5,423	7,312	8,869

Income Statement – Dignitana AB, TSEK

DIGNITANA AB, PARENT COMPANY	Q2 2023	Q2 2022	Q1–Q2 2023	Q1–Q2 2022	Full year 2022
Operating Income					
Net sales	4,104	3,311	7,559	5,814	12,140
Capitalized work for own account	0	0	0	0	431
Other operating income	2,001	5,774	2,117	6,391	9,453
Total Operating Income	6,105	9,085	9,676	12,205	22,024
Operating expense					
Goods for Resale	-1,786	-962	-2,034	-2,196	-5,911
Operating expense	-2,122	-3,790	-4,176	-6,309	-21,666
Personnel expense	-4,453	-1,787	-8,561	-3,141	-10,242
Depreciation and amortization of tangible and intangible assets	-1,155	-1,131	-2,308	-4,385	-6,659
Other operating expenses	-256	-46	-317	-175	-431
	-9,772	-7,716	-17,396	-16,206	-44,909
Operating profit (loss)	-3,667	1,369	-7,720	-4,001	-22,885
Result from financial investments					
Other Interest income and similar items	573	186	583	256	992
Interest expenses and similar items	-221	-12	-345	-56	-712
	352	174	238	200	280
Profit after financial items	-3,315	1,543	-7,482	-3,801	-22,605
Profit before tax	-3,315	1,543	-7,482	-3,801	-22,605
Results for the Period	-3,315	1,543	-7,482	-3,801	-22,605

Balance Sheet – Dignitana AB, TSEK

DIGNITANA AB, PARENT COMPANY	2023-06-30	2022-06-30	2022-12-31
ASSETS			
FIXED ASSETS			
Intangible assets			
Capitalized expenses for development	4,840	8,932	7,116
	4,840	8,932	7,116
Tangible assets			
Equipment, tools and installations	49	0	0
Other machinery and other technical facilities	45	63	54
Leasing machines	41	78	59
	135	141	113
Financial assets			
Participations in group companies	66,198	522	66,198
Receivable from group companies	8,952	6,643	10,698
Other long term receivables	292	0	175
	75,442	7,165	77,071
Total Fixed Assets	80,417	16,238	84,300
CURRENT ASSETS			
Inventories and similar			
Finished goods and goods for resale	2,211	5,045	2,766
	2,211	5,045	2,766
Current Receivables			
Accounts Receivable	857	1,438	1,470
Receivables from group companies	1,962	62,769	0
Current Tax Assets	0	89	0
Other Current Receivables	461	960	667
Prepaid expenses and accrued income	855	487	446
	4,135	65,743	2,583
Cash and Bank Balances	1,780	2,780	5,455
Total Current Assets	8,126	73,568	10,804
Total Assets	88,543	89,806	95,104
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share Capital	7,047	6,506	7,047
Fund for development expenses	4,840	8,932	7,116
	11,887	15,438	14,163
Non-restricted equity			
Share premium reserves	246,550	223,070	245,866
Other non-restricted equity	-176,399	-157,886	-156,070
Results for the period	-7,482	-3,801	-22,605
	62,669	61,383	67,191
Total Equity	74,556	76,821	81,354
Provisions			
Other provisions	292	0	175
	292	0	175
Current Liabilities			
Accounts payable	650	1,647	921
Current payable to group company	5,960	397	6,592
Other current liabilities	2,243	5,810	1,345
Accrued expenses and deferred income	4,842	5,131	4,717
Total current liabilities	13,695	12,985	13,575
Total liabilities	13,695	12,985	13,575
Total Equity and Liabilities	88,543	89,806	95,104

Financial calendar

16 November 2023

Q3 Report

15 February 2024

2023 Year End Report

All financial reports are available at

www.dignitana.com/investor-relations/financial-reports/

Contact information

Dignitana AB

Traktorgränden 3, 226 60 Lund
+46 (0) 46-16 30 90
info@dignitana.com
investorrelations@dignitana.com
www.dignitana.com

Certified Adviser

Redeye AB
+46 8 121 576 90
certifiedadviser@redeye.se
www.redeye.se